Rabies shot reveals immune secrets in CAR-T cancer survivors
NCT ID NCT04410900
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This study gave a rabies vaccine to people who had CAR-T therapy for B-cell cancers, plus healthy volunteers for comparison. The goal was to see how well the immune system responds to vaccination after CAR-T treatment. Researchers measured antibody levels to gauge immune function, which could help guide future infection prevention in these patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rabies vaccine (Imovax Rabies)
What this could lead to
If successful, this study could help doctors understand how well the immune system works after CAR-T therapy, leading to better infection prevention strategies.
What could go wrong
This is a small, early-phase study that only measures immune response to a vaccine, not a treatment itself. Results may not apply to all patients or predict real-world infection risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.